贝福替尼对比埃克替尼一线治疗EGFR突变晚期非小细胞肺癌的3期研究
这项多中心、开放标签、随机3期研究纳入362例EGFR突变阳性局部晚期或转移性非小细胞肺癌患者,比较贝福替尼与埃克替尼一线治疗的疗效与安全性。贝福替尼组中位无进展生存期显著优于埃克替尼组,但3级及以上治疗相关不良事件发生率更高。
要点
- 贝福替尼组3级及以上治疗相关不良事件发生率为30%,埃克替尼组为8%。
- 贝福替尼组治疗相关严重不良事件发生率为20%,埃克替尼组为3%。
核心结论
- 贝福替尼在EGFR突变阳性非小细胞肺癌一线治疗中疗效优于埃克替尼。
- 贝福替尼严重不良事件更常见,但整体安全性可控。
研究设计与样本
- 多中心、开放标签、随机对照3期研究,在中国39家医院开展。
- 共筛查568例患者,随机分配362例至贝福替尼组(n=182)或埃克替尼组(n=180)。
- 入组患者为18岁及以上、组织学确诊的IIIB、IIIC或IV期不可切除非小细胞肺癌,且确认存在外显子19缺失或外显子21 Leu858Arg突变。
- 随机按1:1分配,分层因素为EGFR突变类型、中枢神经系统转移状态和性别,参与者和研究者均未设盲。
- 主要终点为独立评审委员会评估的全分析集无进展生存期。
主要发现
- 贝福替尼组55例(30%)发生3级及以上治疗相关不良事件,埃克替尼组14例(8%)。
- 贝福替尼组37例(20%)报告治疗相关严重不良事件,埃克替尼组5例(3%)。
- 贝福替尼组2例(1%)和埃克替尼组1例(1%)因治疗相关不良事件死亡。
关键数值与推荐
- 贝福替尼用法为口服75-100 mg每日一次,埃克替尼为口服125 mg每日三次,均21天为一周期。
临床怎么用
- 对于EGFR突变阳性局部晚期或转移性非小细胞肺癌患者,贝福替尼可作为一线治疗选择。
- 使用贝福替尼时需密切监测治疗相关不良事件,尤其是严重不良事件。
局限性
- 研究为开放标签设计,参与者和研究者未设盲。
- 总生存期随访仍在进行中,尚未报告最终总生存数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Befotertinib (D-0316) is a novel, selective oral third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor. This phase 3 trial compared the efficacy and safety of befotertinib with icotinib as a first-line treatment for patients with EGFR mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC). METHODS: This study was a multicentre, open-label, randomised, controlled phase 3 study at 39 hospitals in China. Eligible patients were 18 years of age or older, had histologically confirmed locally advanced or metastatic stage IIIB, IIIC, or IV unresectable NSCLC, and had confirmed exon 19 deletions or exon 21 Leu858Arg mutation. Patients were randomly assigned (1:1) via an interactive web response system to receive either oral befotertinib (75-100 mg once daily) or oral icotinib (125 mg three times per day) in 21-day cycles until disease progression or withdrawal criteria were met. Randomisation was stratified by type of EGFR mutation, CNS metastasis status, and gender, and participants, investigators, and data analysts were not masked to treatment allocation. The primary endpoint was independent review committee (IRC)-assessed progression-free survival in the full analysis set, which comprised all randomly assigned patients. All patients who received at least one dose of the study drug were included in safety analyses. This study was registered with ClinicalTrials.gov, NCT04206072, and the overall survival follow-up is still in progress. FINDINGS: Between Dec 24, 2019, and Dec 18, 2020, 568 patients were screened, of whom 362 were randomly assigned to the befotertinib (n=182) or icotinib (n=180) group; all 362 patients were included in the full analysis set. Median follow-up was 20·7 months (IQR 10·2-23·5) in the befotertinib group and 19·4 months (10·3-23·5) in the icotinib group. Median IRC-assessed progression-free survival was 22·1 months (95% CI 17·9-not estimable) in the befotertinib group and 13·8 months (12·4-15·2) in the icotinib group (hazard ratio 0·49 [95% CI 0·36-0·68], p<0·0001). Grade 3 or higher treatment-related adverse events occurred in 55 (30%) of 182 patients in the befotertinib group and in 14 (8%) of 180 patients in the icotinib group. Treatment-related serious adverse events were reported in 37 (20%) patients in the befotertinib group and in five (3%) patients in the icotinib group. Two (1%) patients in the befotertinib group and one (1%) patient in the icotinib group died due to treatment-related adverse events. INTERPRETATION: Befotertinib demonstrated superior efficacy compared with icotinib in first-line treatment for patients with EGFR mutation-positive NSCLC. Although serious adverse events were more common in the befotertinib than the icotinib arm, the safety profile of befotertinib was manageable overall. FUNDING: Betta Pharmaceuticals (China). TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Lu S, Zhou J, Jian H, et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir Med. 2023. PMID: 37244266. doi:10.1016/S2213-2600(23)00183-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。